The Lone Analyst Who Said Sell Valeant When Hedge Funds Piled In
- Khmelnitsky watched shares double in a year, before crashing
- `I stayed with the call,' Veritas analyst says in interview
Valeant CEO Makes His Case Right to Analysts
This article is for subscribers only.
In July 2014, Dimitry Khmelnitsky advised investors to sell Valeant Pharmaceuticals International Inc. and then watched the stock double in a year.
“It was very painful,” Khmelnitsky, an analyst at Veritas Investment Research Corp., said in an telephone interview from his office in Toronto. “What I felt was pain.”